A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
Neal Van Hoeven(Sana Biotechnology (United States)), Rhea N. Coler(Infectious Disease Research Institute), David E. Clements(Hawaii Biotech (United States)), Christopher B. Fox(Utah State University), Susan L. Baldwin(Seattle Children's Hospital), Timothy Martyak(Hawaii Biotech (United States)), Angela M. Bosco‐Lauth(Colorado State University), Ghislain Ismael Nana(Infectious Disease Research Institute), Steven G. Reed(Infectious Disease Research Institute), Richard A. Bowen(Colorado State University), D E Parks(Hawaii Biotech (United States)), Sharvari Waghmare Joshi(Infectious Disease Research Institute)
Cited by 33
Related Papers
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
|Nature Medicine|2007|1.4k
Key roles of adjuvants in modern vaccines
|Nature Medicine|2013|1.4k
A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission
|Science|2007|582
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air
|Proceedings of the National Academy of Sciences|2009|224
Ecology of Zoonotic Infectious Diseases in Bats: Current Knowledge and Future Directions
|Zoonoses and Public Health|2012|206